Terazosin

• Benign prostatic hyperplasia (BPH) - enlarged prostate
• Hypertension (high blood pressure)
• Urinary retention related to BPH
• Combination therapy for resistant hypertension
• Kidney stones (off-label, to help pass stones)

Terazosin is an oral alpha-1 adrenergic receptor antagonist used for the symptoms of benign prostatic hyperplasia (BPH) and as add-on therapy for hypertension. Marketed as Hytrin, it relaxes smooth muscle in the prostate, bladder neck, and arterial vasculature, improving urinary flow and lowering blood pressure simultaneously. Once-daily dosing and a long history of clinical use make it a reasonable, affordable choice when both conditions coexist, though more selective alpha-blockers such as tamsulosin, silodosin, and alfuzosin have largely supplanted terazosin for BPH alone because they cause less orthostatic hypotension.

Mechanism of Action

Alpha-1 adrenergic receptors are abundant on smooth muscle in the prostate stroma, bladder neck, prostatic urethra, and arterial walls. Norepinephrine release from sympathetic nerve terminals stimulates these receptors, contracting smooth muscle and increasing dynamic urethral resistance — the so-called dynamic component of BPH that adds to the static obstruction caused by prostate enlargement. Terazosin is a long-acting quinazoline derivative that competitively blocks alpha-1A, alpha-1B, and alpha-1D receptors with limited tissue selectivity.

In the lower urinary tract, terazosin relaxes prostatic and bladder neck smooth muscle, reducing urethral resistance and improving urinary flow rate, often within days, without changing prostate size. In the systemic vasculature, alpha-1 blockade causes arterial and venous dilation, lowering peripheral vascular resistance and dropping blood pressure by 8 to 14 mmHg systolic in hypertensive patients. The non-selective profile — meaning terazosin blocks alpha-1B receptors in arterioles in addition to the alpha-1A receptors that predominate in the prostate — is the basis for both its blood pressure lowering and its higher rate of orthostatic hypotension and dizziness compared with prostate-selective agents. Terazosin is well absorbed orally with bioavailability near 90 percent and a half-life of about 12 hours, allowing once-daily dosing. The American Urological Association and American Heart Association provide clinical context.

Clinical Use

For symptomatic BPH, alpha-blockers are first-line for moderate-to-severe lower urinary tract symptoms, particularly when symptoms predominate over prostatic enlargement. Symptom relief — including reduced hesitancy, weaker stream, urinary frequency, urgency, and nocturia — is typically apparent within one to two weeks. Among alpha-blockers, tamsulosin and silodosin are more uroselective and cause less hypotension, making them preferred when blood pressure is normal or already controlled. Terazosin and doxazosin remain useful when the patient also has uncontrolled hypertension, where one drug can address both problems, or when cost is a major factor. For larger prostates above 40 mL, combining an alpha-blocker with a 5-alpha reductase inhibitor such as finasteride or dutasteride reduces both symptoms and risk of progression more than either alone.

For hypertension, current American Heart Association and USPSTF frameworks place alpha-blockers as later-line agents because the ALLHAT trial found doxazosin inferior to thiazide diuretics in preventing heart failure. Alpha-blockers are now used primarily as add-on therapy for resistant hypertension or when a coexisting indication like BPH justifies their use. Patients can review the blood pressure overview for context. Terazosin has been studied off-label for ureteral stone passage, where it relaxes ureteral smooth muscle and may speed expulsion of distal stones.

How to Take It

Terazosin is started at 1 mg taken at bedtime to minimize the first-dose hypotensive effect. The dose is gradually titrated weekly to 2 mg, 5 mg, and up to 10 to 20 mg daily based on response and tolerance. Most BPH patients respond best at 10 mg; hypertension may require higher doses. The first dose, every titration step, and any dose taken after missing more than several days should be at bedtime, and patients should be cautioned to rise slowly from sitting or lying down for the first several days. Tablets can be taken with or without food and are stored at room temperature.

If a dose is missed and the next dose is more than 12 hours away, take it; otherwise skip it and resume normally — never double up. Critically, if a patient stops terazosin for more than several days, the entire titration must be restarted at 1 mg to avoid syncope. Co-administration with phosphodiesterase-5 inhibitors such as sildenafil or tadalafil for erectile dysfunction can produce additive hypotension; the smallest effective dose of the PDE5 inhibitor is recommended, with separation by at least four hours. NSAIDs may modestly blunt the antihypertensive effect.

First-week experience often includes mild dizziness on standing, fatigue, and nasal congestion that improve over two to four weeks. Patients should know that any planned cataract surgery requires informing the ophthalmologist about alpha-blocker use because of the risk of intraoperative floppy iris syndrome.

Monitoring and Follow-Up

Baseline blood pressure (sitting and standing), heart rate, and urinary symptom score such as the International Prostate Symptom Score (IPSS) help quantify benefit. Postvoid residual measurement, urinalysis, and PSA testing per shared decision-making with the USPSTF are part of standard BPH workup. Renal function and electrolytes are checked as part of overall hypertension management.

During titration, blood pressure is checked sitting and standing within the first one to two weeks, watching for orthostatic drops greater than 20 mmHg systolic or 10 mmHg diastolic with positional change. Symptom score is reassessed at 4 to 6 weeks; substantial improvement should be apparent by 8 weeks. If urinary symptoms remain inadequately controlled, options include increasing the dose, adding a 5-alpha reductase inhibitor for larger prostates, or referral for surgical or minimally invasive evaluation. Annual reassessment of symptoms, postvoid residual, and renal function is appropriate.

Special Populations

Elderly patients are particularly vulnerable to orthostatic hypotension, dizziness, and fall-related injuries; conservative dose titration and bedtime dosing are especially important. No formal renal dose adjustment is required, though caution is reasonable in severe impairment. Hepatic dose reduction has not been formally established; cautious titration is sensible. Terazosin is not indicated in women, in pregnancy, or in pediatric patients. Patients with a history of orthostatic syncope, those on multiple antihypertensives, and those on PDE5 inhibitors require slower titration and closer monitoring. Patients planning cataract or any intraocular surgery should inform the surgeon, since intraoperative floppy iris syndrome can occur even after the drug has been discontinued.

When to Contact Your Doctor

Call for any episode of fainting or near-fainting, persistent severe dizziness on standing, falls, fast or irregular heartbeat, or chest pain. A painful erection lasting more than four hours (priapism) is a urologic emergency and requires immediate evaluation. New shortness of breath, leg swelling, or rapid weight gain may suggest fluid retention. Inability to urinate, blood in the urine, fever with urinary symptoms, or worsening urinary retention deserves prompt assessment. Discuss any planned eye surgery, new prescription, or new over-the-counter medication, particularly other antihypertensives or PDE5 inhibitors. If you stop terazosin for more than several days for any reason, do not resume the previous dose — call for guidance on safe re-titration.

Terazosin is available generically and remains one of the most affordable BPH and antihypertensive options, which can be a meaningful consideration for patients without prescription coverage. Beyond the medication itself, patients with BPH benefit from a few practical adjustments. Limiting fluid intake in the two to three hours before bedtime reduces nighttime awakenings; minimizing caffeine and alcohol — both bladder irritants and diuretics — often improves urgency and frequency. Double voiding (urinating, waiting a minute, then trying again) can reduce postvoid residual. Many over-the-counter cold and allergy products contain decongestants like pseudoephedrine or first-generation antihistamines that worsen urinary retention; these should be avoided. Constipation aggravates urinary symptoms and deserves attention. For hypertension, the DASH eating pattern, regular aerobic exercise, sodium reduction below 2,300 mg daily, weight loss when applicable, and limiting alcohol all amplify medication effects. Blood pressure measured at home with a validated cuff in the morning and evening provides better data than occasional office readings. Patients should bring a log of home readings and a list of all current medications to each follow-up visit so the regimen can be optimized rather than guessed.

For a coordinated plan that addresses BPH symptoms, blood pressure, and overall cardiovascular risk in St. Petersburg, contact us or schedule a visit with our internal medicine team.